Article
Immunology
Kameliya Vinketova, Vesselina Koleva, Elena Puncheva, Suzana Nashar, Tsvetelina Oreshkova
Summary: Maternal immunity regulates tolerance to the fetus during pregnancy through immune regulatory factors. CD83 levels in the serum of pregnant women decrease as pregnancy progresses and recover to non-pregnant levels in miscarriage. Serum CD83 levels are negatively correlated with rising progesterone and estradiol levels, suggesting that the regulation of CD83 levels may depend on pregnancy hormones and other unknown factors.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY
(2022)
Article
Immunology
Meng Feng, Xin Wang, Shuping Zhou, Minghao Li, Tingting Liu, Xunbin Wei, Wei Lin
Summary: CD83(+) B cells are the main source of sCD83, which alleviates the symptoms of experimental autoimmune uveitis (EAU) and reduces the percentage of T cells and DCs in the eyes and lymph nodes. These CD83(+) B cells decrease IL-1 beta, IL-18, and IFN-gamma secretion by DCs through sCD83. sCD83 interacts with GTPase Ras-related protein (Rab1a) in DCs to promote Rab1a accumulation in autolysosomes and inhibit mTORC1 phosphorylation and NLRP3 expression. Therefore, CD83(+) B cells play a regulatory role in EAU by secreting sCD83. The lack of regulation of CD83(+) B cells may be an important factor leading to hyperimmune activation in patients with autoimmune uveitis. CD83(+) B cells suppress activated DCs in uveitis, indicating the potential therapeutic role of CD83(+) B cells in uveitis.
Letter
Medicine, General & Internal
Anna R. Schreiber, Dara L. Aisner, Jonathan A. Gutman
Summary: This article reports a case of fetal-induced graft-versus-host disease, in which the mother developed fever, pancytopenia, and rash 3 weeks after the delivery of twin sons that included transfusion.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Cell Biology
Wei Lin, Shuping Zhou, Meng Feng, Yong Yu, Qinghong Su, Xiaofan Li
Summary: The study demonstrated that sCD83 inhibits T cell activation by disrupting DC-T contact and immunological synapse formation, mainly through disrupting F-actin rearrangements in dendritic cells. This novel signaling pathway may be a potential target for developing new immunosuppressive therapies for autoimmune diseases.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Immunology
Hua Jiang, Denggang Fu, Alan Bidgoli, Sophie Paczesny
Summary: Allogeneic hematopoietic cell transplantation (allo-HCT) is crucial for treating hematological malignancies, but acute and chronic graft-versus-host disease (aGVHD and cGVHD) are major complications. Understanding the roles of T cell subsets in GVHD pathogenesis is essential for identifying new therapeutic targets and improving outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Linde Dekker, Evy Sanders, Caroline A. Lindemans, Coco de Koning, Stefan Nierkens
Summary: The recovery of naive T cells plays an important role in allo-HCT by functioning as both drivers and regulators in allogeneic reactions. Adequate reconstitution of naive T cells can improve GvHD prevention while maintaining GvL effects to lower relapse risk.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Shuang Fan, Wen-Xuan Huo, Yang Yang, Meng-Zhu Shen, Xiao-Dong Mo
Summary: This study reports the updated results of ruxolitinib as treatment for SR-GVHD and compares the efficacy and safety between children and adults. The findings suggest that ruxolitinib is an effective and safe treatment for SR-GVHD, and both children and adults can benefit from it.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Hematology
Noa G. Holtzman, Steven Z. Pavletic
Summary: Chronic graft-versus-host disease (cGVHD) is a systemic complication of allogeneic haematopoietic stem cell transplantation that can lead to increased morbidity and mortality. Despite limited curative treatment options, recent collaborative research efforts have led to discovery of new second-line therapies. Comprehensive and sustained multidisciplinary efforts are crucial for successful management of cGVHD.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shinri Sato, Eisuke Shimizu, Jingliang He, Mamoru Ogawa, Kazuki Asai, Hiroyuki Yazu, Robert Rusch, Mio Yamane, Fan Yang, Shinji Fukuda, Yutaka Kawakami, Kazuo Tsubota, Yoko Ogawa
Summary: In this study, it was found in a mouse model that gentamicin (GM) significantly suppressed systemic cGVHD phenotypes and ocular manifestations, and reduced inflammatory cell infiltration and fibrosis in cGVHD-targeted organs. Although GM maintained higher levels of regulatory T cells, there were fewer Th17 cells and IL-6-producing macrophages in cGVHD-targeted organs. These findings suggest that orally administered GM may have positive effects in a cGVHD mouse model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Konradin F. Muskens, Caroline A. Lindemans, Mirjam E. Belderbos
Summary: GvHD is a major complication of HCT, causing severe hematopoietic dysfunction. Immune activation during GvHD damages hematopoietic stem cells and their niche in the bone marrow, leading to reduced functionality. Complications and treatments associated with HCT exacerbate hematopoietic dysfunction.
Review
Immunology
Fathima A. Mohamed, Govindarajan Thangavelu, Stephanie Y. Rhee, Peter T. Sage, Roddy S. O'Connor, Jeffrey C. Rathmell, Bruce R. Blazar
Summary: The therapeutic efficacy of allo-HSCT is limited by the development of GVHD, with immune dysregulation leading to expansion of alloreactive cells and reduction in regulatory cells. New therapies are needed to restore the balance between effector and regulatory immune cells while preserving the beneficial graft-versus-tumor effect.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study evaluated the effects of ruxolitinib compared with basiliximab in the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had a higher overall response rate and effectively prevented chronic GVHD (cGVHD), leading to improved survival rates.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study retrospectively evaluated the effects of ruxolitinib compared with basiliximab for steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had higher overall response and complete response rates, as well as lower incidence of chronic GVHD. Ruxolitinib also improved overall survival and failure-free survival rates. In addition, ruxolitinib significantly reduced the occurrence of EBV viremia. Therefore, ruxolitinib should be recommended for the treatment of SR-aGVHD.
ANNALS OF HEMATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Alfonso Rodriguez-Gil, Estrella Carrillo-Cruz, Cristina Marrero-Cepeda, Guillermo Rodriguez, Jose A. Perez-Simon
Summary: Vitamin D plays a dual role in the immune system and tumor cells, potentially decreasing graft-versus-host disease and relapse rates.
Review
Immunology
Xianjing Cheng, Ruihao Huang, Shiqin Huang, Wei Fan, Rongdi Yuan, Xiaoqi Wang, Xi Zhang
Summary: Ocular graft-versus-host disease (GVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation. It greatly impacts the quality of life of affected individuals due to impaired visual function, pain, and other symptoms. However, the diagnosis and treatment of ocular GVHD pose challenges for hematologists and ophthalmologists, as there are no unified international criteria. This review explores the complex pathogenesis of ocular GVHD, providing a comprehensive summary of the disease's pathogenic mechanisms, related tear biomarkers, and clinical characteristics. Novel therapies based on these mechanisms are also discussed, offering new insights into ocular GVHD treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
